History of Medimabs

Founded in 2006, in Montreal, Quebec, by a group of McGill University researchers to ensure affordable access by local researchers to the latest high-quality research antibodies. Our goal was to offer custom antibody generation services and provide better, faster and cheaper than most research laboratories could do it for themselves.

As of 2018, our facilities are now located in the heart of Montreal surrounded by the Montreal’s life science cluster with many biotech companies, Universities, R&D institutions, major healthcare networks and hospitals. New premises but the company focus is still the same with the added benefit of offering new innovative services and a complete “One stop shop” for all your antibody needs.

Our services

Board of Directors

Dr. Moussa B.H. Youdim

BSc, MsC, PhD

Member of the Board of Directors

Member of the Scientific Advisory Committee

Dr Youdim is the Finkelstein Professor of Life Sciences and Professor of Pharmacology at the Technion-Rappaport Family Faculty of Medicine, the Director of the Eve Topf and National Parkinson Foundation (USA) Neurodegenerative Disease Research and Teaching Centers of Excellence and the Chief Executive Officer of ABITAL Pharma Pipeline Ltd.

Dr Youdim is internationally renowned for his research in depressive illness, Parkinson’s disease and Alzheimer’s disease. His research at Oxford University led to the discovery of the monoamine oxidase B inhibitor, l-deprenyl (selegiline) as an anti-Parkinson drug in 1975 which was responsible for changing the prospects of treating Parkinson’s disease and other neuro-degenerative disorders. His research at the Technion has led to the development of the second generation of monoamine oxidase inhibitor anti-Parkinson drug, Rasagiline and multifucntional neuroprotective anti-Alzheimers drug Ladostigil and more recently iron chelators HLA-20 and M30 for treatment of amyotrophic lateral sclerosis and Alzheimer’s disease. Rasagiline and its derivatives account for more than 90 international patents in the field of neuropsychiatric drug development held by Dr Youdim.

Dr Youdim serves as a consultant for several major international pharmaceutical companies and joined MédiMabs’ Scientific Advisory Board as well as the Board of Directors in 2015.

Dr. Eduardo L. Franco

BSc, MPH, DrPH, FRSC, FCAHS, OC, PhD (Hon.)

Member of the Scientific Advisory Committee

Dr. Franco is James McGill Professor in the Departments of Oncology and Epidemiology & Biostatistics, Director, Division of Cancer Epidemiology, and Chairman, Department of Oncology, at McGill University’s Faculty of Medicine. He was previously a faculty member at the Université du Québec, Senior Researcher and Head of the Epidemiology Unit at the  Ludwig Institute for Cancer Research, Brazil. Dr Franco holds BSc (1975) and Licentiate (1976) degrees in biology from UniCamp (Universidade de Campinas, Brazil), and master’s (MPH) and doctoral (DrPH) degrees in public health microbiology from the University of North Carolina at Chapel Hill. He was a Guest Researcher at the U.S. Centers for Disease Control, in Atlanta, and a post-doctoral fellow in cancer epidemiology during 1984 at the International Agency for Research on Cancer in Lyon, France, at the U.S. National Cancer Institute (NCI) in Bethesda, and at Louisiana State University, in New Orleans. Dr Franco’s research has focuses on the following topics: molecular epidemiology and prevention of cervical cancer and human papillomavirus-associated diseases, cancers of the upper aero-digestive tract, prostate, endometrium, and childhood tumours; studies of epidemiologic methods for evaluating efficacy of cancer screening strategies; the impact of measurement error in epidemiology; and studies of societal and clinical influences on cancer patient survival. Much of his research has been international, with collaborative projects in Canada, Brazil, Mexico, the Congo Republic, United States, and with the International Agency for Research on Cancer, in France.

He is the Editor-in-Chief of Preventive Medicine (2013-18) and Founding Editor of Preventive Medicine Reports (2014-18) and serves on the editorial boards of several bio-medical journals He has served in several scientific or grant review panels as well as an advisor to the US President’s Cancer Panel (2012, 2013).  Dr Franco was inducted as Officer of the Order of Canada (2016), and over the span of his career received several awards and honours in cancer, epidemiology and biostatistics, and recognition as a CIHR Distinguished Scientist, and holds the James McGill Professorship

Dr. Michel L. Tremblay

PhD F.R.S.C.

Member of the Scientific Advisory Committee

Dr Tremblay is a James McGill Professor and former director of the Goodman Cancer Research Centre at McGill University, Montreal, Quebec.  Dr. Tremblay has been recognized at each stage of his scientific career by awards that recognize his excellence as a cancer researcher. He is the Jeanne and J-Louis Levesque Chair in Cancer Research, honoured with the Robert L Noble Award of the Canadian Cancer Society and is Chevalier of the Ordre National du Quebec.

His laboratory works on characterizing the function and regulation of several members of the Protein Tyrosine Phosphatase (PTP) gene family using both biochemical and genetic approaches.  Dr. Tremblay has over 10 patents filed and over 140 publications in the field of Protein Tyrosine Phosphatases and he is a recognized figure internationally on this gene family and their function in cancer, diabetes and neuroscience. Based on his expertise, he served on several boards of biotech/pharma industry companies, two of which he initiated the foundation, and he continues to pursue various research projects in partnership with the private sector. He served as the first coordinator of the Quebec Node of the Terry Fox Research Institute and was member of the Scientific Committee of the Québec Consortium for Drug Discovery.
He is recipient of an FRSQ chercheur national; honored as the Jeanne and J.–Louis Lévesque Chair in Cancer Research and as a Fellow to the Academy of Sciences of the Royal Society of Canada.

He recently undertook several new assignments, such as; being the secretary general of the International Society of Pathophysiology, and a member of the Advisory Committee on Research for the Canadian Cancer Society.

Get in touch